Substituted thioureas as heat shock protein 70 inhibitors

US9718770B2 · kind B2 · utility

Assignee

• INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES · CN

Inventors

• Wu Zhong · Beijing, CN
• Song Li · Beijing, CN
• Yanqun ZENG · Beijing, CN
• Junhai Xiao · Beijing, CN
• Xinbo Zhou · Beijing, CN
• Zhibing Zheng · Beijing, CN
• Xingzhou Li · Beijing, CN
• Xiaokui Wang · Beijing, CN

Key dates

• Filing date: Dec 18, 2014
• Grant date: Aug 1, 2017
• Expiry date: Dec 18, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/16
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides a compound of Formula I, an isomer, a pharmaceutically acceptable salt, or a solvate thereof, and use thereof in manufacture of a medicament for preventing and/or treating a drug-resistant tumor or disease or disorder caused by a drug-resistant bacterium, or use thereof in manufacture of a medicament for preventing and/or treating a tumor, a neurodegenerative disease, an allogeneic graft rejection, or an infection-associated disease or disorder; preferably, the tumor, neurodegenerative disease, allogeneic graft rejection, or infection-associated disease or disorder is a disease or disorder caused by Heat shock protein 70 (Hsp70). The compounds of the invention, which are a class of Hsp70 inhibitors having a novel structure and a high activity, solve the problem concerning drug resistance of tumors, enhance the effect of treating tumors, and provide a new medical strategy for treatment of tumors in clinic.